Episode Details

Back to Episodes
Dry Eye Disease: August 2026 Phase II/III Results for Novel Mechanisms

Dry Eye Disease: August 2026 Phase II/III Results for Novel Mechanisms

Published 2 months, 3 weeks ago
Description

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/dry-eye-disease-august-2026-phase-ii-iii-results-for-novel-mechanisms

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

Dry Eye Disease: August 2026 Phase II/III Results for Novel Mechanisms Evidence cutoff: August 22, 2026 Introduction Dry eye disease treatment is moving beyond “replace the tears” with artificial tears. Newer therapies are attempting to stimulate the eye’s own tear reflex, restore the mucin layer, slow tear evaporation, improve meibomian gland function, or target inflammation in genetically selected patients. A date clarification is important: there was not one single August 2026 wave of completed Phase II or Phase III dry eye readouts covering all of these mechanisms. The most important recent human data available by August 22, 2026 include: The May 2026 publication of Phase III results for acoltremon, now marketed in the United States as Tryptyr. A 2026 randomized study of the mucin secretagogues diquafosol and rebamipide, showing effects within 30 minutes. A July 2026 randomized study of lipid-containing artificial tears in people with a thin tear-film lipid layer. Continuing Phase II/III programs for AZR-MD-001, licaminlimab, PL9643, and platelet-lysate biologics, for which definitive August 2026 efficacy results were not publicly posted. An August 8, 2026 publication involving troxipide nanoparticles applied through the eyelid was preclinical animal research, not a human Phase II or Phase III trial. It should not be interpreted as proof of clinical benefit in patients. Troxipide nanoparticle study () How to Interpret Dry Eye Trial Results Clinical trials usually measure both symptoms and signs: Symptoms Assessment iN Dry Eye, or SANDE, measures the frequency and severity of symptoms on a 0-to-100 scale. Higher scores indicate worse symptoms. Ocular Surface Disease Index, or OSDI, measures symptoms and their effect on daily activities. Higher scores indicate worse disease. Tear break-up time, often called TBUT, measures how long the tear film remains stable after a blink. A longer time is generally better. Corneal fluorescein staining measures damage to the surface cells of the cornea. A lower score is better. Schirmer testing estimates tear production using a paper strip. A larger increase suggests more aqueous tear production. These measures do not always improve together. A patient may have less burning but little change in staining, or may produce more tears without feeling much better. This symptom–sign mismatch is one of the major difficulties in dry eye research. Results also cannot be compared directly across studies unless the trial populations, control groups, dosing schedules, and measurement methods are similar. Summary of the Most Relevant 2026 Evidence For the full table, please open this article on visualfieldtest.com. Neurosensory Modulation: Acoltremon, or Tryptyr Mechanism and treatment concept Tryptyr contains acoltremon, a transient receptor potential melastatin 8 agonist. Transient receptor potential melastatin 8 channels are found on cold-sensitive sensory nerves in the cornea and eyelids. Activating these nerves can stimulate a reflex pathway involving the lacrimal gland and increase tear production. The mechanism is different from anti-inflammatory drugs such as cyclosporine and lifitegrast. It also differs from Miebo, which is designed primarily to reduce evaporation. The Food and Drug Administration review noted that acoltremon’s tear-producing effect is greatly reduced under topical an

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us